Romanos Sklavenitis-Pistofidis, MD, Dana-Farber Cancer Institute, Boston, MA, describes a novel risk stratification model for asymptomatic Waldenström’s macroglobulinemia (WM), sharing some insights into the parameters in this model and statistics on its usage. Dr Sklavenitis-Pistofidis also highlights the importance of early intervention in asymptomatic WM, and the need to further research and integrate risk stratification models across cohorts of patients. To conclude, Dr Sklavenitis-Pistofidis explains how bone marrow immune profiling may provide insights into disease progression, and allow for better approaches to early intervention. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.